IRS ELISA Kits
Insulin Receptor Substrate (IRS) proteins are pivotal in insulin signaling, acting as intermediaries between the insulin receptor and downstream effectors. Among the IRS family, IRS1 and IRS2 are extensively studied for their roles in metabolic regulation and their implications in conditions like insulin resistance and type 2 diabetes.
Key Features:
- Sensitivity and Specificity: Designed to detect low concentrations of IRS proteins with high specificity, minimizing cross-reactivity with similar proteins.
- Assay Range: Typically, these kits offer a detection range suitable for physiological and pathological levels of IRS proteins. For example, the Human IRS1 ELISA Kit from Abcam has a detection range of 0.219–14 ng/mL with a sensitivity of 0.096 ng/mL. Abcam
- Sample Types: Validated for use with various sample matrices, including cell lysates, serum, plasma, and tissue homogenates, providing versatility for different research needs.
- Assay Time: The total assay duration varies but generally ranges from 1.5 to 4 hours, facilitating efficient processing of multiple samples.
Applications:
- Metabolic Research: IRS proteins are integral to insulin signaling pathways. Measuring their levels is essential in studies related to glucose metabolism, insulin resistance, and diabetes.
- Cell Signaling Studies: IRS proteins serve as docking platforms for various signaling molecules. Quantifying IRS proteins can aid in understanding cellular responses to insulin and other growth factors.
- Pharmacological Research: In drug development, IRS protein levels serve as biomarkers to evaluate the efficacy of therapeutic agents targeting insulin signaling pathways. Monitoring IRS proteins can help determine the impact of therapeutic interventions aimed at modulating insulin sensitivity.
By providing accurate quantification of IRS protein levels, these ELISA kits are invaluable tools in metabolic research, cell signaling studies, and pharmacological investigations, facilitating studies on insulin signaling, metabolic disorders, and the efficacy of therapeutic interventions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|